Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German specialty pharmaceutical company, granting Qingfeng exclusive development and commercialization rights to Inbrija (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of on-off (OFF) episodes in adult patients with Parkinson’s disease (PD) across mainland China, Hong Kong, and Macau.
Deal Structure & Strategic Framework
| Partnership Element | Details |
|---|---|
| Parties | Qingfeng Pharmaceutical (licensee) / Merz Therapeutics (licensor) |
| Asset | Inbrija (levodopa inhalation powder) + inhalation device |
| Territory | Mainland China, Hong Kong, and Macau (Greater China) |
| Indication | Intermittent treatment of OFF episodes in adult PD patients on levodopa/DDCI therapy |
| Qingfeng Responsibilities | Local development, regulatory filing, commercialization, clinical funding |
| Merz Responsibilities | Product supply, global quality assurance, overseas drug registration holder |
| Financial Terms | Undisclosed upfront payment + development/commercial milestones + tiered supply prices + royalties |
The partnership establishes a clear division of responsibilities leveraging Merz’s global manufacturing expertise and Qingfeng’s local regulatory and commercial capabilities.
Asset Profile & Clinical Differentiation
- Product: Inbrija (levodopa inhalation powder) – first-in-class inhaled levodopa formulation
- Regulatory Status: FDA approved (2018) and EMA approved (2019) for PD OFF episode management
- Target Population: Adult PD patients already receiving levodopa/dopa-decarboxylase inhibitor (DDCI) therapy
- Key Innovation: Pulmonary delivery bypasses gastrointestinal absorption issues common in PD
- Clinical Advantage: Unaffected by food intake or PD-related GI conditions that interfere with oral medication absorption
Parkinson’s Disease Market Opportunity
| Market Context | Details |
|---|---|
| PD Prevalence in China | Estimated 3-4 million patients; growing rapidly with aging population |
| OFF Episode Burden | 40-60% of advanced PD patients experience unpredictable OFF episodes |
| Current Treatment Gap | Limited options for rapid rescue therapy during OFF episodes |
| Competitive Landscape | Oral rescue medications face absorption challenges; injectable options have compliance barriers |
| Inbrija Differentiation | Rapid onset (within minutes), non-invasive administration, reliable absorption regardless of GI status |
Commercial Strategy & Market Access
Regulatory Pathway
- Local Registration: Qingfeng to lead NMPA submission leveraging existing FDA/EMA approvals
- Registration Holder Structure: Merz as overseas holder, Qingfeng as local responsible party
- Accelerated Review Potential: Priority review possible given unmet medical need and established safety profile
Commercial Infrastructure
- Target Setting: Neurology clinics, movement disorder centers, and hospital pharmacies
- Pricing Strategy: Premium pricing justified by innovative delivery and clinical benefits
- Market Education: Significant investment required in physician and patient education on inhalation technique
- Reimbursement Strategy: Pursuit of national reimbursement listing to ensure broad access
Strategic Implications & Industry Impact
- First-Mover Advantage: Inbrija represents the first inhaled levodopa therapy in Greater China
- Platform Validation: Success could establish Qingfeng as preferred partner for European CNS innovations
- Investment Signal: Demonstrates continued international confidence in China’s specialty pharmaceutical market
- Patient Impact: Addresses critical unmet need for reliable, rapid-acting OFF episode rescue therapy
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market penetration, and commercial performance. Actual results may differ due to risks including regulatory decisions, market adoption rates, competitive dynamics, and execution challenges.-Fineline Info & Tech
